← Leaderboards
Yan Q. Xiong
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
$2,961,057
Attributed
$2,961,057
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $778.9K · FY2012–23$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,961,057 · 3
By mechanism
R01$2,571,486 · 2
R21$389,571 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroInfectionCommunitiesBacteremiaGenesAntibioticsResistanceStaphylococcus AureusIn VivoMutantDaptomycinGeneticMolecularMorbidity - Disease RateNeutrophilMediatingBacteriaLaboratoriesMedicalInfective EndocarditisLifeEventAntibiotic ResistanceGenotype
Grant awards (8)
The role of purine biosynthesis and stringent response in persistent MRSA endovascular infections$450,790
R01 · FY2023 · AI · contact PI
Bicarbonate-Mediated Enhancement of Beta-Lactam-MRSA Killing: Mechanisms and Clinical Translatability$328,099
R01 · FY2023 · AI · contact PI
The role of purine biosynthesis and stringent response in persistent MRSA endovascular infections$450,790
R01 · FY2022 · AI · contact PI
The role of purine biosynthesis and stringent response in persistent MRSA endovascular infections$350,807
R01 · FY2021 · AI · contact PI
The role of purine biosynthesis and stringent response in persistent MRSA endovascular infections$490,169
R01 · FY2020 · AI · contact PI
The role of purine biosynthesis and stringent response in persistent MRSA endovascular infections$500,831
R01 · FY2019 · AI · contact PI
Early agr Activation is a Key Pathogenic Signature in Persistent MRSA Bacteremia$206,561
R21 · FY2013 · AI · contact PI
Early agr Activation is a Key Pathogenic Signature in Persistent MRSA Bacteremia$183,010
R21 · FY2012 · AI · contact PI